UK markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.1750-0.0550 (-4.47%)
As of 03:57PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.2300
Bid1.1900 x 4000
Ask1.2000 x 2200
Day's range1.1700 - 1.2400
52-week range1.1400 - 5.6000
Avg. volume1,417,040
Market cap194.903M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.2900
Earnings date10 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.55
  • Globe Newswire

    atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

    RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophreniaGRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical developmentCOMP360: Recently announced acceleration of the Pivotal Trial 1 (COMP 005) part of the phase 3 program, with top line data now expected in the summer of 2024Corporate: As a result of our recent restructuring and pipeline updates, the company has extended its cash r

  • Globe Newswire

    atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

    NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. Details of the company’s panel participation are as follows: Cowen 43rd Annual Health Care Conference Format: Neuropsych Corporate Panel Date and Time: Monday, March 6th, 12:50 p.m. – 1:20 p.m. ET Location: Boston, MA A live webc

  • Globe Newswire

    atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

    GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day.Final results demonstrate target engagement of GRX-917 via dose-related activation of quantitative electroencephalography (qEEG) frontal beta power, a biomarker for GABA-A receptor-associated anxiolytic activity, consistent with GRX-917’s puta